Vanguard Group
LRMR icon

Vanguard Group’s Larimar Therapeutics LRMR Stock Holding History

Vanguard Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$11.6M Sell
3,046,216
-41,624
-1% -$162K ﹤0.01% 2888
2025
Q3 		$9.97M Buy
3,087,840
+945,809
+44% +$3.55M ﹤0.01% 2977
2025
Q2 		$6.19M Sell
2,142,031
-75,777
-3% -$175K ﹤0.01% 3136
2025
Q1 		$4.77M Buy
2,217,808
+24,883
+1% +$78.7K ﹤0.01% 3187
2024
Q4 		$8.49M Sell
2,192,925
-104,324
-5% -$689K ﹤0.01% 3042
2024
Q3 		$15M Sell
2,297,249
-240,240
-9% -$1.93M ﹤0.01% 2742
2024
Q2 		$18.4M Buy
2,537,489
+169,788
+7% +$1.3M ﹤0.01% 2612
2024
Q1 		$18M Buy
2,367,701
+912,458
+63% +$7.11M ﹤0.01% 2656
2023
Q4 		$6.62M Buy
1,455,243
+27,516
+2% +$92.8K ﹤0.01% 3173
2023
Q3 		$5.64M Buy
1,427,727
+36,126
+3% +$137K ﹤0.01% 3198
2023
Q2 		$4.36M Buy
1,391,601
+100,191
+8% +$409K ﹤0.01% 3373
2023
Q1 		$5.85M Buy
1,291,410
+204,996
+19% +$1.07M ﹤0.01% 3226
2022
Q4 		$4.49M Buy
1,086,414
+131,654
+14% +$449K ﹤0.01% 3355
2022
Q3 		$3.06M Buy
954,760
+443,678
+87% +$1.11M ﹤0.01% 3579
2022
Q2 		$1M Hold
511,082
– – ﹤0.01% 4091
2022
Q1 		$2.07M Sell
511,082
-14,961
-3% -$97.9K ﹤0.01% 3944
2021
Q4 		$5.68M Buy
526,043
+115,727
+28% +$1.29M ﹤0.01% 3536
2021
Q3 		$4.73M Sell
410,316
-254,054
-38% -$3.05M ﹤0.01% 3698
2021
Q2 		$6.53M Buy
664,370
+188,834
+40% +$2.13M ﹤0.01% 3446
2021
Q1 		$6.95M Buy
475,536
+12,860
+3% +$234K ﹤0.01% 3356
2020
Q4 		$9.9M Buy
462,676
+240,015
+108% +$4.81M ﹤0.01% 3001
2020
Q3 		$3.38M Buy
222,661
+139,956
+169% +$1.77M ﹤0.01% 3325
2020
Q2 		$1.06M Sell
82,705
-2
-0% -$23 ﹤0.01% 3601
2020
Q1 		$764K Hold
82,707
– – ﹤0.01% 3566
2019
Q4 		$1.1M Hold
82,707
– – ﹤0.01% 3616
2019
Q3 		$734K Sell
82,707
-32,294
-28% -$354K ﹤0.01% 3725
2019
Q2 		$1.64M Sell
115,001
-24,888
-18% -$663K ﹤0.01% 3528
2019
Q1 		$4.6M Buy
139,889
+14,226
+11% +$729K ﹤0.01% 3168
2018
Q4 		$7.46M Buy
125,663
+3,281
+3% +$324K ﹤0.01% 2911
2018
Q3 		$17.2M Buy
122,382
+15,116
+14% +$1.83M ﹤0.01% 2649
2018
Q2 		$13.2M Buy
107,266
+30,948
+41% +$2.63M ﹤0.01% 2764
2018
Q1 		$6.82M Buy
76,318
+5,768
+8% +$489K ﹤0.01% 3012
2017
Q4 		$3.91M Sell
70,550
-8,179
-10% -$369K ﹤0.01% 3219
2017
Q3 		$3.33M Buy
78,729
+5,076
+7% +$211K ﹤0.01% 3258
2017
Q2 		$3.1M Buy
73,653
+9,992
+16% +$511K ﹤0.01% 3254
2017
Q1 		$3.56M Buy
63,661
+4,164
+7% +$207K ﹤0.01% 3188
2016
Q4 		$2.27M Sell
59,497
-19,962
-25% -$810K ﹤0.01% 3322
2016
Q3 		$3.16M Buy
79,459
+12,345
+18% +$561K ﹤0.01% 3213
2016
Q2 		$4.82M Buy
67,114
+10,321
+18% +$816K ﹤0.01% 3001
2016
Q1 		$4.55M Buy
56,793
+2,175
+4% +$172K ﹤0.01% 3000
2015
Q4 		$4.12M Sell
54,618
-2,120
-4% -$341K ﹤0.01% 3074
2015
Q3 		$21.8M Buy
56,738
+13,088
+30% +$5.9M ﹤0.01% 2254
2015
Q2 		$18.1M Buy
43,650
+13,124
+43% +$5.49M ﹤0.01% 2410
2015
Q1 		$14.5M Buy
30,526
+13,499
+79% +$6.41M ﹤0.01% 2469
2014
Q4 		$6.3M Buy
17,027
+6,792
+66% +$1.75M ﹤0.01% 2771
2014
Q3 		$2.41M Buy
+10,235
New +$2.32M ﹤0.01% 3184

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's LRMR Position: Q4 2025 in Review

Vanguard Group reduced its Larimar Therapeutics (LRMR) stake by 1.3% in Q4 2025, selling an estimated $162K and leaving 3,046,216 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2888.

Vanguard Group first reported a position in LRMR in Q3 2014 and has held it in 46 quarters since. The position peaked at $21.8M in Q3 2015. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

  • Vanguard Group held 3,046,216 shares of Larimar Therapeutics worth $11.6M as of Q4 2025.
  • Vanguard Group sold 41,624 Larimar Therapeutics shares in Q4 2025, an estimated $162K.
  • Larimar Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2888 holding.
  • Vanguard Group first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 46 quarters since.
  • Vanguard Group's Larimar Therapeutics position peaked at $21.8M in Q3 2015.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.